Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimized rhTPO (TPIAO) vs Eltrombopag in Previously Treated Primary ITP
NCT05583838Phase 4Completed
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Nov 2022
- Primary completion
- Feb 2024
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of recombinant human thrombopoietin in primary immune thrombocytopenia (ITP) (2 arms), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Median time to achieve platelet count ≥50x10^9/L at 6 weeks. Started Nov 2022; status: completed.
02
Drugs
recombinant human thrombopoietin
03
Conditions
primary immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT05583838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05583838.